BioLife Solutions (NASDAQ:BLFS) Cut to Hold at Zacks Research

BioLife Solutions (NASDAQ:BLFS) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research note on Monday, November 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.20.

BioLife Solutions Trading Down 0.8%

NASDAQ BLFS opened at $24.75 on Monday. BioLife Solutions has a 12 month low of $19.10 and a 12 month high of $29.62. The stock’s fifty day moving average price is $26.55 and its 200-day moving average price is $24.42. The stock has a market cap of $1.19 billion, a P/E ratio of -353.52 and a beta of 1.93.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 30,000 shares of BioLife Solutions stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $25.72, for a total value of $771,600.00. Following the completion of the sale, the chief financial officer owned 152,769 shares of the company’s stock, valued at approximately $3,929,218.68. The trade was a 16.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Greef Roderick De sold 31,165 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $25.33, for a total transaction of $789,409.45. Following the sale, the chief executive officer owned 389,998 shares of the company’s stock, valued at approximately $9,878,649.34. This represents a 7.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 935,727 shares of company stock valued at $26,269,334. Company insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

Several large investors have recently modified their holdings of BLFS. Amalgamated Bank lifted its holdings in BioLife Solutions by 3.5% in the third quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 366 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 441 shares during the period. Louisiana State Employees Retirement System increased its position in shares of BioLife Solutions by 2.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock valued at $454,000 after purchasing an additional 500 shares during the last quarter. Isthmus Partners LLC increased its position in shares of BioLife Solutions by 0.4% during the 2nd quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after purchasing an additional 509 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in shares of BioLife Solutions by 0.5% in the 1st quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock worth $2,695,000 after purchasing an additional 547 shares during the period. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.